US Patent

US10435404 — Formulations of a compound modulating kinases

Formulation · Assigned to Daiichi Sankyo Co Ltd · Expires 2038-07-24 · 12y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects formulations of a compound, specifically Pexidartinib hydrochloride, in combination with a solubilizing agent.

USPTO Abstract

Provided are compositions comprising Compound I having the following structure: or a pharmaceutically acceptable salt thereof, and a solubilizing agent; methods of making the same; and methods of using the same.

Drugs covered by this patent

pexidartinib-hydrochloride (PEXIDARTINIB HYDROCHLORIDE)

Patent Metadata

Patent number: US10435404
Jurisdiction: US
Classification: Formulation
Expires: 2038-07-24
Drug substance claim: No
Drug product claim: Yes
Assignee: Daiichi Sankyo Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.